Cleaning composition, method of making and use thereof

ABSTRACT

A method for formulating a cleaning composition contains the step of coating a granular absorbent material with a coating agent to produce a coated absorbent material and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition. The resulting cleaning composition may be used for cleaning up pathogens or hazardous materials. The cleaning composition may also functions as a liquefiable dry cleaning powder for public areas in response to bodily fluid incidents. A coating method of a non-toxic bio static film on a high surface area solid is disclosed.

This application is a Continuation of U.S. application Ser. No.16/135,568, filed Sep. 19, 2018, which is a Continuation of U.S.application Ser. No. 15/696,480, filed Sep. 6, 2017, which claimspriority of U.S. Provisional Application Ser. No. 62/495,274, filed onSep. 8, 2016. The entirety of which is incorporated herein by reference.

FIELD

The present application generally relates to a cleaning compositions andmethods and, in particular, relates to a cleaning composition and methodfor cleaning up a surface, such as disinfecting, or removing a biohazardmaterial from, a public area.

BACKGROUND

Typically, different types of disinfectants have been utilized asreplacements to heat sterilization, radiation sterilization, or otherless desirable techniques, in a variety of industries, including thepharmaceutical and medical industries, for some time. Disinfectantseffectuate a safer, more cost effective and/or convenient means ofeliminating potentially harmful germs, viruses, funguses and bacteria.However, the inherent strength of the chemical disinfectant has at timesresulted in effectiveness and cost outweighing safety. Consequently,great care must be taken by the user regarding the nature of the use towhich a chemical disinfectant is being put and there are stringentguidelines placed on all chemical disinfectant compositions.

SUMMARY

One aspect of the present application is directed to a method offormulating a cleaning composition, comprising the steps of: coating agranular absorbent material with a coating agent to produce a coatedabsorbent material; and mixing the coated absorbent material with asanitation agent, wherein the coated absorbent material absorbs thesanitation agent to form the cleaning composition.

Another aspect of the present application directs to a cleaningcomposition, comprising an granular absorbent material coated with abiocide; and a sanitation agent absorbed in said granular absorbentmaterial.

Another aspect of the present application directs to a method forprevention and/or decontamination of a surface from a pathogen,comprising: applying an effective amount of a cleaning composition onsaid surface, wherein said cleaning composition comprises an granularabsorbent material coated with a biocide; and a sanitation agentabsorbed in the granular absorbent material. In one embodiment, thepathogen is a virus or bacteria.

Yet, another aspect of the present application directs to a sanitationmethod, comprising the step of: applying an effective amount of thecleaning composition which comprises an granular absorbent materialcoated with a biocide; and a sanitation agent absorbed in said granularabsorbent material to a surface in need of sanitation; and removing thecleaning composition after a period of time.

Another aspect of the present application directs to as a cleaning kitcomprising the cleaning composition which comprises an granularabsorbent material coated with a biocide; and a sanitation agentabsorbed in said granular absorbent material to a surface in need ofsanitation, and instructions on how to use the cleaning composition.

Another aspect of the application is a specialized coating method of anon-toxic bio static film on a high surface area solid, such as agranular absorbent material.

These and other aspects and embodiments of the present application willbecome better understood with reference to the following detaileddescription when considered in association with the accompanyingdrawings and claims.

DETAILED DESCRIPTION

The aspects of the application are described in conjunction with theexemplary embodiments, including methods, materials and examples, suchdescription is non-limiting and the scope of the application is intendedto encompass all equivalents, alternatives, and modifications, eithergenerally known, or incorporated here. Unless otherwise defined, alltechnical and scientific terms used herein have the same meaning ascommonly understood by one of ordinary skill in the art to which thisapplication belongs. One of skill in the art will recognize manytechniques and materials similar or equivalent to those described here,which could be used in the practice of the aspects and embodiments ofthe present application. The described aspects and embodiments of theapplication are not limited to the methods and materials described.

As used in this specification and the appended claims, the singularforms “a,” “an” and “the” include plural referents unless the contentclearly dictates otherwise.

Ranges may be expressed herein as from “about” one particular value,and/or to “about” another particular value. When such a range isexpressed, another embodiment includes from the one particular valueand/or to the other particular value. Similarly, when values areexpressed as approximations, by use of the antecedent “about,” it isunderstood that the particular value forms another embodiment. It isfurther understood that the endpoints of each of the ranges aresignificant both in relation to the other endpoint, and independently ofthe other endpoint. It is also understood that there are a number ofvalues disclosed herein, and that each value is also herein disclosed as“about” that particular value in addition to the value itself. Forexample, if the value “10” is disclosed, then “about 10” is alsodisclosed. It is also understood that when a value is disclosed that“less than or equal to “the value,” greater than or equal to the value”and possible ranges between values are also disclosed, as appropriatelyunderstood by the skilled artisan. For example, if the value “10” isdisclosed the “less than or equal to 10” as well as “greater than orequal to 10” is also disclosed.

This application describes a novel, effective and low cost cleaningcomposition that can be used for rapid and safe clean-up of a surface.bio hazard spills (vomit/urine/blood and feces) in hospitals, urgentcare facilities, medical offices, nursing homes, prisons, schools andthe hospitality industry. This method and formulation is also ideallysuited for common, highly hazardous spills in these environments, e.g.,spills of chemotherapy drugs.

Method of Making

One aspect of the present application is directed to a method of makinga cleaning composition. The method comprises the steps of coating agranular absorbent material with a coating agent to produce a coatedabsorbent material; and mixing the coated absorbent material with asanitation agent, wherein the coated absorbent material absorbs thesanitation agent to form a coated and absorbed absorbent material. Insome embodiments, the method further comprises the step of grinding anabsorbent material to produce the granular absorbent material used inthe coating step. In other embodiments, the method further comprises thestep of adding one or more modifying agent to the coated and absorbedabsorbent material in amounts sufficient to achieve desired physicalcharacteristics (e.g., non-dusty and clump, ease of pick up, liquidloading capacity, etc.).

The cleaning composition may be used to eradicate, eliminate,inactivate, inhibit the activity of, or reduce the amount of pathogenson a surface. The cleaning composition is especially for the clean-up ofbiohazard spills, such as vomit, urine, blood and feces in hospitals,urgent care facilities, medical offices, nursing homes, prisons, schoolsand the hospitality industry. The cleaning composition of the presentapplication is also ideally suited for clean-up of common, highlyhazardous spills in these environments, such as spills of chemotherapydrugs.

The Granular Absorbent Material

The granular absorbent material can be any solid material with desiredsurface area, granulation, and absorbent characteristics. As usedherein, the term “absorbent” or “adsorbent” is understood to mean amaterial that is capable of imbibing and holding onto aqueous fluids.Suitable granular absorbent material include, but are not limited to,expanded and optimized ceramic minerals such perlite and vermiculite,zeolite, activated carbon, cellulosic absorbents and fibrous absorbents.In some embodiments, the granular absorbent material contains activatedcarbon, fumed silica, fine perlite, zeolites, processed clays orcombinations thereof. The adsorbent/absorbent will exhibit clumping ormatting characteristics for best performance and be well de-dusted. Thegranular absorbent material preferably has a surface area per mass orvolume ratio. In some embodiments, the granular absorbent material has asurface area per mass ratio in the range of 100-10,000 m²/g, 100-9,000m²/g, 100-8,000 m²/g, 300-8,000 m²/g, 1,000-8,000 m²/g, 2,000-8,000m²/g, 3,000-8,000 m²/g, 4,000-8,000 m²/g, 5,000-8,000 m²/g, 6,000-8,000m²/g, 7,000-8,000 m²/g, 100-7,000 m²/g, 300-7,000 m²/g, 1,000-7,000m²/g, 2,000-7,000 m²/g, 3,000-7,000 m²/g, 4,000-7,000 m²/g, 5,000-7,000m²/g, 6,000-7,000 m²/g, 100-6,000 m²/g, 300-6,000 m²/g, 1,000-6,000m²/g, 2,000-6,000 m²/g, 3,000-6,000 m²/g, 4,000-6,000 m²/g, 5,000-6,000m²/g, 100-4,000 m²/g, 300-4,000 m²/g, 1,000-4,000 m²/g, 2,000-4,000m²/g, 3,000-4,000 m²/g, 100-3,000 m²/g, 300-3,000 m²/g, 1,000-3,000m²/g, 2,000-3,000 m²/g, 100-2,000 m²/g, 300-2,000 m²/g, or 1,000-2,000m²/g.

In some embodiments, the granular absorbent material has a surface areaper mass ratio up to 10,000 m²/g. In some embodiments, the granularabsorbent material has a surface area per mass ratio up to 9,000 m²/g.In some embodiments, the granular absorbent material has a surface areaper mass ratio up to 8,000 m²/g. In some embodiments, the granularabsorbent material has a surface area per mass ratio up to 7,000 m²/g.In some embodiments, the granular absorbent material has a surface areaper mass ratio up to 6,000 m²/g.

In some embodiments, the granular absorbent material has a surface areaper mass ratio of 100 m²/g or greater. In some embodiments, the granularabsorbent material has a surface area per mass ratio of 300 m²/g orgreater. In some embodiments, the granular absorbent material has asurface area per mass ratio of 1,000 m²/g or greater. In someembodiments, the granular absorbent material has a surface area per massratio of 2,000 m²/g or greater. In some embodiments, the granularabsorbent material has a surface area per mass ratio of 3,000 m²/g orgreater. In some embodiments, the granular absorbent material has asurface area per mass ratio of 4,000 m²/g or greater. In someembodiments, the granular absorbent material has a surface area per massratio of 5,000 m²/g or greater.

In some embodiments, the granular absorbent material has a surface areaper mass ratio in the range of 1000-6,000 m²/g.

In some embodiments, the granular absorbent material contains ceramicminerals.

In some embodiments, the granular absorbent material contains perliteand/or vermiculite.

In some embodiments, the granular absorbent material has a surface areaper volume ratio in the range of 100-5,000 m²/ml, 300-5,000 m²/ml,1,000-5,000 m²/ml, 2,000-5,000 m²/ml, 3,000-5,000 m²/ml, 4,000-5,000m²/ml, 100-4,000 m²/ml, 300-4,000 m²/ml, 1,000-4,000 m²/ml, 2,000-54,000m²/ml, 3,000-4,000 m²/ml, 100-3,000 m²/ml, 300-3,000 m²/ml, 1,000-3,000m²/ml, 2,000-3,000 m²/ml, 100-2,000 m²/ml, 300-2,000 m²/ml, or1,000-2,000 m²/ml.

In some embodiments, the granular absorbent material has a surface areaper volume ratio up to 5,000 m²/ml. In some embodiments, the granularabsorbent material has a surface area per volume ratio up to 4,000m²/ml. In some embodiments, the granular absorbent material has asurface area per volume ratio up to 3,000 m²/ml.

In some embodiments, the granular absorbent material has a surface areaper volume ratio of 100 m²/ml or greater. In some embodiments, thegranular absorbent material has a surface area per volume ratio of 300m²/ml or greater. In some embodiments, the granular absorbent materialhas a surface area per volume ratio of 1,000 m²/ml or greater. In someembodiments, the granular absorbent material has a surface area pervolume ratio of 2,000 m²/ml or greater. In some embodiments, thegranular absorbent material has a surface area per volume ratio in therange of 1000-3,000 m²/ml.

As used herein, the term “ceramics” shall mean compounds of nonmetallicelements possessing in general hardness, compressive strength, elasticmodulus, thermal expansion and density. Exemplary ceramics include, butare not limited to, materials used in pottery, bricks, tiles, cementsand glass, barium titanate, strontium titanate, bismuth strontiumcalcium copper oxide, boron oxide, boron nitride, earthenware, ferrite,lead zirconate titanate, magnesium diboride, porcelain, sialon, siliconcarbodie, silicon nitride, steatite, titanium carbide, uranium oxide,yttrium barium copper oxide, zinc oxide, zirconium dioxide, andpartially stabilized zirconia. Ceramics may be oxides (aluminia,beryllia, ceria, zirconia), nonoxides (carbide, boride, nitride,silicide) or composite materials (combinations of oxides and onoxides).

Perlite is a naturally occurring form of obsidian characterized byspherulites formed by cracking of volcanic glass during cooling. Perlitetypically comprises a mix of silicon dioxide, aluminium oxide, sodiumoxide, potassium oxide, iron oxide, magnesium oxide and calcium oxide.Potential substitutes for perlite include, but are not limited to,diatomite, expanded clay, shale, pumice, slag or vermiculite.Vermiculite is a naturally occurring hydrous phyllosilicate material,which is 2:1 clay.

As used herein, the term “zeolite” shall mean any of a large group ofminerals comprising hydrated aluminosilicates of sodium, potassium,calcium and barium. Zeolite can occur naturally, but is alsoartificially synthesized. Exemplary zeolites include, but are notlimited to, analcime, chabazite, clinoptilolite, heulandite, natrolite,phillipsite, and stilbite.

As used herein, the term “activated carbon” shall mean a form of carbonprocessed to have small, low-volume pores that increase the surface areaavailable for adsorption or chemical reactions. A synonym for activatecarbon is “activated charcoal.”

As used herein, the term “cellulosic absorbents” shall mean celluloseand cellulose derivatives that can provide structure, bulk,water-holding capacity and channeling of fluids over a wide dimensionalrange.

As used herein, the term “fibrous absorbents” refers to a fibrousstructure with high void volume, a hydrophilic nature, and wetresiliency. Examples of fibrous absorbents include, but are not limitedto, cotton fiber based absorbents, corn fiber based absorbents and hempbased absorbents.

In some embodiments, the granular absorbent material constitutes 10-70%(w/w), 10-60% (w/w), 10-50% (w/w), 10-40% (w/w), 10-30% (w/w), 10-20%(w/w), 20-70% (w/w), 20-60% (w/w), 20-50% (w/w), 20-40% (w/w), 20-30%(w/w), 30-70% (w/w), 30-60% (w/w), 30-50% (w/w), 30-40% (w/w), 40-70%(w/w), 40-60% (w/w), 40-50% (w/w), 50-70% (w/w), 50-70% (w/w) or 60-70%(w/w) of the final product. In some embodiments, the granular absorbentmaterial constitutes 25-30% (w/w) of the final product. In someembodiments, the granular absorbent material constitutes about 27% (w/w)of the final product.

The Coating Agent

The coating agent can be any biocide capable of forming a coating layeron the surface of the granular absorbent material of the presentapplication. In some embodiments, the coating agent contains one or moreagents selected from the group consisting of silanes, siloxanes,aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides,solutions of silver, solutions of copper and combinations thereof.

In some embodiments, the coating agent is a biocide that forms a surfacebonded film on the granular absorbent material. The static surfacebonded biocide film provides a long term inactivation or inhibition ofpathogens in contact with the cleaning composition of the presentinvention, thus providing a long term assurance of the effectiveness ofthe cleaning effect. In some embodiments, the coating agent is appliedto the granular absorbent material by vapor deposition. In someembodiments, the vapor deposition is performed by thermal heating thecoating agent and the granular absorbent.

In some embodiments, the coating agent is applied to the granularabsorbent material by pressure micro droplet spray.

In some embodiments, the coating agent is applied to the granularabsorbent material by a fuming or fogging nozzle.

In some embodiments, the coating agent is applied to the granularabsorbent material by a deposition technique commonly used for metalplating.

As used herein, the term “biocide” refers to any material that destroys,inactivates, eliminates, deters, inhibits the growth of, or otherwiserender harmless and/or prevent damage or infection of a pathogen or amicroorganism. Examples of biocide includes, but are not limited to,silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines,fumed metal hydroxides, silver and salts or solutions thereof, copperand salts or solutions thereof, formaldehyde; bronopol; chlorocresol;peracetic acid; chloroxylenol; biphenyl-2-ol; hexa-2,4-dienoicacid/scorbutic acid; glutaral; clorofen; 2-phenoxyethanol;cetylpyridinium chloride; tosylchloramide sodium; sodium 2-biphenylate;phthalaldehyde; N-(3-aminopropyl)-N-dodecylpropan-1,3-diamine; troclosensodium; sodium dichloroisocyanurate dihydrate; didecyldimethylammoniumchloride; iodine; sodium hypochlorite; hydrogen peroxide; calciumhypochlorite; silver chloride; lignin; 2,2-dibromo-2-cyanoacetamide;sodium p-chloro-m-cresolate; d-gluconic acid compound withN,N″-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediamidine(2:1); potassium (E,E)-hexa-2,4-dienoate; quaternary ammonium compounds,benzyl-C12-18-alkyldimethyl-chlorides;benzyl-C12-16-alkyldimethyl-chlorides; di-C8-10-alkyldimethyl-chlorides;pentapotassium bis(peroxymonosulfate)-bis(sulfate);benzyl-C12-14-alkyldimethyl-chlorides;C12-14-alkyl[(ethylphenyl)methyl]dimethyl-chlorides;[2-[[2-[(2-carboxyethyl)(2-hydroxyethyl)-amino]ethyl]amino]-2-oxoethyl]-cocoalkyldimethyl-hydroxides, internal salts; reaction products from:glutamic acid and N-(C12-14-alkyl)-propylenediamine;6-(phthalimido)peroxyhexanoic acid; silver sodium hydrogen zirconiumphosphate; poly(hexamethylendiamineguanidinium chloride);polyhexamethylene biguanide; oligo(2-(2-ethoxy)ethoxyethylguanidiniumchloride) polymer; amines, n-C10-16-alkyltrimethylene di-, reactionproducts from chloroacetic acid; quaternary ammonium iodides;benzylalkyldimethyl(alkyl from C8-C22, saturated and unsaturated, andtallow alkyl, coco alkyl and soya alkyl), chlorides, bromides orhydroxides)/BKC; dialkyldimethyl(alkyl from C6-C18, saturated andunsaturated, and tallow alkyl, coco alkyl and soya alkyl) chlorides,bromides or methylsulfates)/DDAC; 2-butanone, peroxide; boric acid;disodium octaborate tetrahydrate; triclosan; melaleuca alternifolia,extract/Australian tea tree oil; sulfur dioxide; sodium hydrogensulfite; disodium disulfite; sodium sulfite; potassium sulfite;dipotassium disulfite;1-[[2-(2,4-di-chlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazol/propiconazole;triclocarban; dodecylguanidine monohydrochloride; silver zinc aluminumborophosphate glass/glass oxide, silver and zinc-containing; aluminumsodium silicate silver zinc complex/silver-zinc zeolite plant protectionagents; sodium benzoate; disodium-tetraborate, anhydrous; mixture of cisand trans p-menthan-3,8-diol/citriodiol; mecetronium ethyl sulfate;amines, C10-16-alkyldimethyl-, N-oxides; calcium dihexa-2,4-dienoate;sodium hydrogen carbonate; benzoxonium chloride; benzethonium chloride;tetradonium bromide; polyvinylpyrrolidone-iodine; silver nitrate;N,N′-(decan-1,10-diyldi-1(4H)-pyridyl-4-yliden)bis(octylammonium)dichloride;2,4,8,10-tetra(tert-butyl)-6-hydroxy-12H-dibenzo[d,g][1,3,2]dioxaphosphocin-6-oxide,sodium-salt.

As used herein, the term “silanes” refers chemical compounds with foursubstituents on silicon, including an organosilicon compound. Exemplarysilanes include, but are not limited to, trichlorosilane (SiHCl₃),tetramethylsilane (Si(CH₃)₄) and tetraethoxysilane (Si(OC₂H₅)₄).

As used herein, the term “siloxanes” refers to chemical compounds thatcontain a functional group in organosilicon chemistry with the Si—O-Ailinkage. Exemplary siloxanes include, but are not limited to,polydimethylsiloxane or cyclomethicones.

As used herein, the term “pathogen” includes, but is not limited to,viruses, bacteria, yeast, protozoan, or other pathogenic microorganisms.Definitions and description of pathogens that may be eliminated, killed,inactivated or inhibited by administering the cleaning composition ofthe present application are described below. One of ordinary skill willunderstand that the described pathogens herein are not limiting. In someembodiments, the biocide and/or the cleaning composition of the presentapplication can address such critical pathogen families as norovirus,HIV, MRSA, C. Diff., hepatitis, ebola, GI-related viruses of many sortsor targeted bioterror agents, amongst others defined and describedbelow.

Examples of viruses include, but are not limited to, influenza viruses,herpesviruses, polioviruses, noroviruses, gastrointestinal tract-related(GI-related) viruses and retroviruses. Examples of viruses include, butare not limited to, human immunodeficiency virus type 1 and type 2(HIV-1 and HIV-2), human T-cell lymphotropic virus type I and type II(HTLV-I and HTLV-II), hepatitis A virus, hepatitis B virus (HBV),hepatitis C virus (HCV), hepatitis delta virus (HDV), hepatitis E virus(HEV), hepatitis G virus (HGV), parvovirus B19 virus, transfusiontransmitted virus (TTV), Epstein-Barr virus, human cytomegalovirus type1 (HCMV-1), human herpesvirus type 6 (HHV-6), human herpesvirus type 7(HHV-7), human herpesvirus type 8 (HHV-8), influenza type A viruses,including subtypes H1N1 and H5N1, influenza type B viruses, humanmetapneumovirus, severe acute respiratory syndrome (SARS) coronavirus,hantavirus, and RNA viruses from Arenaviridae (e.g., Lassa fever virus(LFV)), Pneumoviridae (e.g., human metapneumovirus), Filoviridae (e.g.,Ebola virus (EBOV), Marburg virus (MBGV) and Zika virus); Bunyaviridae(e.g., Rift Valley fever virus (RVFV), Crimean-Congo hemorrhagic fevervirus (CCHFV), and hantavirus); Flaviviridae (West Nile virus (WNV),Dengue fever virus (DENV), yellow fever virus (YFV), GB virus C (GBV-C;formerly known as hepatitis G virus (HGV)); Rotaviridae (e.g.,rotavirus), human T-cell lymphotropic virus (HTLV) type I and type II(HTLV-I and HTLV-II), parvovirus B19 virus, transfusion transmittedvirus (TTV); measles virus; rotaviruses, including Types A, B, C, D, andE; human papilloma virus (HPV) and its many serotypes; and othermiscellaneous RNA viruses.

Examples of microbes caused causing gastroenteritis in man and animalsinclude, viruses, bacteria, parasites and fungus. Viruses cause ˜7-% ofinfectious diarrhea. Viral infections causing gastroenteritis can beattributed to rotavirus, adenovirus, norovirus, astrovirus, andcoronavirus. Bacterial infections leading to gastroenteritis can becaused by Campylobacter, Escherichia coli, Salmonella, Shigella,Staphylococcus aureus, and Clostridum bacterial species. Protozoainfections leading to gastroenteritis can be a result of Giardia,Entamoeba, and Cryptosporidium species.

As used herein, the term “bacteria” shall mean members of a large groupof unicellular microorganisms that have cell walls but lack organellesand an organized nucleus. Synonyms for bacteria include the terms“microorganisms”, “microbes”, “germs”, “bacilli”, “pathogens”, and“prokaryotes.” Exemplary bacteria include, but are not limited toMycobacterium species, including M. tuberculosis; Staphylococcusspecies, including S. epidermidis, S. aureus, and methicillin-resistantS. aureus; Streptococcus species, including S. pneumoniae, S. pyogenes,S. mutans, S. agalactiae, S. equi, S. canis, S. bovis, S. equinus, S.anginosus, S. sanguis, S. salivarius, S. mitis; other pathogenicStreptococcal species, including Enterococcus species, such as E.faecalis and E. faecium; Haemophilus influenzae, Pseudomonas species,including P. aeruginosa, P. pseudomallei, and P. mallei; Salmonellaspecies, including S. enterocolitis, S. typhimurium, S. enteritidis, S.bongori, and S. choleraesuis; Shigella species, including S. flexneri,S. sonnei, S. dysenteriae, and S. boydii; Brucella species, including B.melitensis, B. suis, B. abortus, and B. pertussis; Neisseria species,including N. meningitidis and N. gonorrhoeae; Escherichia coli,including enterotoxigenic E. coli (ETEC); Vibrio cholerae, Helicobacterpylori, Chlamydia trachomatis, Clostridium difficile, Cryptococcusneoformans, Moraxella species, including M. catarrhalis, Campylobacterspecies, including C. jejuni; Corynebacterium species, including C.diphtheriae, C. ulcerans, C. pseudotuberculosis, C.pseudodiphtheriticum, C. urealyticum, C. hemolyticum, C. equi; Listeriamonocytogenes, Nocardia asteroides, Bacteroides species, Actinomycetesspecies, Treponema pallidum, Leptospirosa species, Klebsiellapneumoniae; Proteus sp., including Proteus vulgaris; Serratia species,Acinetobacter, Yersinia species, including Y. pestis and Y.pseudotuberculosis; Francisella tularensis, Enterobacter species,Bacteroides species, Legionella species, Borrelia burgdorferi, and thelike.

As used herein, the term “MRSA” shall mean the gram-positive bacteriummethicillin-resistant Staphylococcus aureus (MRSA). The term MRSAencompasses any strain of S. aureus that has developed, throughhorizontal gene transfer and natural selection, multiple drug resistanceto beta-lactam antibiotics.

As used herein, the term “C. Diff.” shall mean a species ofgram-positive spore-forming bacterium known as Clostridium difficile, orC. difficile, or C. diff or sometimes CDF/cdf. Clostridium difficileinfection (CDI) is a symptomatic infection caused by this bacteria whichcan cause C. difficile associated diarrhea or Clostridum difficilecolitis.

As used herein, the term “fungi” shall mean any member of the group ofsaprophytic and parasitic spore-producing eukaryotic typicallyfilamentous organisms formerly classified as plants that lackchlorophyll and include molds, rusts, mildews, smuts, mushrooms, andyeasts. Exemplary fungi include, but are not limited to, Aspergillusspecies, Dermatophytes, Blastomyces derinatitidis, Candida species,including C. albicans and C. krusei; Malassezia furfur, Exophialawerneckii, Piedraia hortai, Trichosporon beigelii, Pseudallescheriaboydii, Pneumocystis jiroveci, Madurella grisea, Histoplasma capsulatum,Sporothrix schenckii, Histoplasma capsulatum, Tinea species, includingT. versicolor, T. pedis T. unguium, T. cruris, T. capitus, T. corporis,T. barbae; Trichophyton species, including T. rubrum, T. interdigitale,T. tonsurans, T. violaceum, T. yaoundei, T. schoenleinii, T. megninii,T. soudanense, T. equinum, T. erinacei, and T. verrucosum; Mycoplasmagenitalia; Microsporum species, including M. audouini, M. ferrugineum,M. canis, M. nanum, M. distortum, M. gypseum, M. fulvum, and the like.

As used herein, the term “protozoan” shall mean any member of a diversegroup of eukaryotes that are primarily unicellular, existing singly oraggregating into colonies, are usually nonphotosynthetic, and are oftenclassified further into phyla according to their capacity for and meansof motility, as by pseudopods, flagella, or cilia. Exemplary protozoansinclude, but are not limited to Plasmodium species, including P.falciparum, P. vivax, P. ovale, and P. malariae; Leishmania species,including L. major, L. tropica, L. donovani, L. infantum, L. chagasi, L.mexicana, L. panamensis, L. braziliensis and L. guyanensi;Cryptosporidium, Isospora belli, Toxoplasma gondii, Trichomonasvaginalis, and Cyclospora species.

As used herein, the term “targeted bioterror agents” includes, but isnot limited to, anthrax (Bacillus anthracis), botulism (Clostridiumbotulinum toxin), plague (Yersinia pestis), smallpox (Variola virus),tularemia (Franciscella tularensis) and viral hemorrhagic fever(arenaviruses, bunyaviruses, filoviruses, and arenaviruses), or otherCDC Category A Agents. Brucella species, Clostrodium perfringens,Salmonella species, Escherichia coli, and Shigella species, Burkholderiamallei, Burkholderia pseudomallei, Chlamydia psittaci, Coxiellabrunetii, Ricinus communis, Rickettsia prowazekii, Vibrio cholera, andCryptosporidium parvum, and alphaviruses, e.g., Venezuelan equineencephalitis, eastern equine encephalitis, and western equineencephalitis viruses and other CDC Category B Agents. Emerginginfectious disease infectious agents such as Nipah virus, hantavirus andother CDC Category C Agents.

In some embodiments, the coating agent is added in an amount thatconstitutes 0.1 to 10% (w/w), 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to1% (w/w), 0.1 to 0.5% (w/w), 0.3 to 10% (w/w), 0.3 to 5% (w/w), 0.3 to2% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 5% (w/w), 1 to 2% (w/w),3 to 10% (w/w) or 3 to 5% (w/w) of the final product.

In some embodiments, the coating agent is added in an amount thatconstitutes 0.5 to 3.5% (w/w) or 1 to 3% (w/w) of the final product. Insome embodiments, the coating agent is added in an amount thatconstitutes about 2% (w/w) of the final product.

The Sanitation Agent

The sanitation agent can be any agent having biocide activity and can beabsorbed by the coated granular absorbent of the present application.The sanitation agent comprise an active substance designed to destroy,inhibit, reduce activity, inhibit grow or otherwise render harmlessharmful organisms or toxic chemicals. In some embodiments, thesanitation agent is a liquid phase agent. In some embodiment, thesanitation agent is a liquid phase biocide. In some embodiment, thesanitation agent is a liquid phase chemical that inactivates or removestoxic chemicals, such as chemo therapy drugs. In some embodiments, theliquid phase biocide is added at an application site to provide chemicaldisinfection for immediate response.

Examples of liquid phase biocide include, but are not limited to,chlorine bleach solutions, hydrogen peroxide solutions, peracetic acid,quaternary amine solutions, alcohol solutions, periodine solutions,dimethyl benzyl ammonium chloride, dimethyl ethybenzyl ammonium chlorideand mixtures thereof.

Examples of liquid phase chemicals that can be used to inactivate orremove toxic chemicals include, but are not limited to, anionicsurfactants such as soap, sulfonates and sulfates. In some embodiments,large quantities of water is used to dilute the toxic chemicals.

In some embodiments, the sanitation agent is added in an amount thatconstitutes 0.1 to 10% (w/w), 0.1 to 3% (w/w), 0.1 to 1% (w/w), 0.1 to0.3% (w/w), 0.3 to 10% (w/w), 0.3 to 3% (w/w), 0.3 to 1% (w/w), 1 to 10%(w/w), 1 to 3% (w/w) or 3 to 10% (w/w) of the final product.

In some embodiments, the sanitation agent comprises dimethyl benzylammonium chloride or dimethyl ethybenzyl ammonium chloride. In someembodiments, the sanitation agent comprises a mixture of dimethyl benzylammonium chloride or dimethyl ethybenzyl ammonium chloride. In someembodiments, the sanitation agent is a 1:1 mixture of dimethyl benzylammonium chloride or dimethyl ethybenzyl ammonium chloride.

In some embodiments, the sanitation agent is a quaternary amine and isadded in an amount that constitutes 0.3 to 3% (w/w), 0.5 to 2% (w/w) or0.5 to 1.5% (w/w) of the final product. In some embodiments, thesanitation agent is a quaternary amine and is added in an amount thatconstitutes about 1% (w/w) of the final product.

The Modifying Agent

The modifying agent is added to the coated granular absorbent or theabsorbed-and-coated granular absorbent in an amount to achieve desiredphysical characteristics (e.g., non-dusty and clump, ease of pick up,liquid loadability, etc.) in the final product. Examples of themodifying agent include, but are not limited to, thickening agents,gums, absorbent polymers, tackifiers, and combinations thereof.

As used herein, the term “thickening agent” may include any materialknown or otherwise effective in providing suspending, gelling,viscosifying, solidifying or thickening properties to the composition orwhich otherwise provide structure to the final product form. Thesethickening agents may include gelling agents, polymeric or nonpolymericagents, inorganic thickening agents, or viscosifying agents. The amountand type of the thickening agent may vary depending upon the desiredcharacteristics of the final product.

As used herein, the term “tackifier” refers to polymeric adhesives whichincrease the tack, i.e., the inherent stickiness or self-adhesion, ofthe compositions so that after a short period of gentle pressure theyadhere firmly to surfaces. Examples of suitable tackifiers comprisehigh-flexibility resins such as, but not limited to, homopolymers ofalkyl(meth)acrylates, especially alkyl acrylates, such as poly(isobutylacrylate) or poly(2-ethylhexyl acrylate), linear polyesters, as commonlyused for coil coating, linear difunctional oligomers, curable withactinic radiation, with a number average molecular weight of more than2000, in particular from 3000 to 4000, based on polycarbonatediol orpolyester-diol, linear vinyl ether homopolymers or copolymers based onethyl, propyl, isobutyl, butyl and/or 2-ethylhexyl vinyl ether, ornonreactive urethane urea oligomers, which are prepared frombis(4,4-isocyanatophenyl)methane, N,N-dimethylethanolamine or diols suchas propanediol, hexanediol or dimethylpentanediol.

In some embodiments, the modifying agent comprises a high-molecularsubstance that absorbs liquids, preferably water, swells, and finally isconverted to a viscous true or colloidal solution.

In some embodiments, the modifying agent comprises one or more siliconegums. As used herein, the term “silicone gum” means a silicone polymerhaving a degree of polymerization sufficient to provide a siliconehaving a gum-like texture. In certain cases the silicone polymer formingthe gum may be crosslinked.

In some embodiments, the modifying agent comprises a polymer. As usedherein, Examples of the polymers include, but is not limited to, naturaland synthetic polymers such as polyacrylamide (ACAM) and carboxymethylcellulose.

In some embodiments, the polymers of the present application includes,but are not limited to, polyacrylates such as sodium polyacrylates, andcarboxymethyl cellulose.

In some embodiments, the modifying agent comprises one or moresuper-absorbent polymer. The term “super-absorbent polymer” isunderstood to mean hydrophilic polymer structure capable of absorbingwater or saline solution at greater than 10 g of pure water/saline pergram of dry-based material (>10 g/g). Examples of super-absorbentpolymers include, but are not limited to, sodium polyacrylates andcarboxymethyl cellulose.

In some embodiments, the one or more modifying agents further compriseone or more additives selected from the group comprising denaturingagents, colorant agents, odor correctors, and/or pH regulators.

In some embodiments, the one or more modifying agents are added in anamount that constitute 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1%(w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1%(w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the finalproduct.

The Cleaning Composition

Another aspect of the present application relates to a cleaningcomposition. The cleaning composition contains an granular absorbentmaterial coated with a coating agent. Examples of the coating agent havebeen described above. In some embodiments, the coating agent contains abiocide. In some embodiments, the biocide comprises an agent selectedfrom the group consisting of silanes, siloxanes,aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides,silver and salts of silver, copper and salts of copper. In someembodiments, the biocide forms a static film on the surface of thegranular absorbent material. In some embodiments, the granular absorbentmaterial contains activated carbon, fumed silica, fine perlite,zeolites, processed clays or combinations thereof. In some embodiments,the coating agent constitutes 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1%(w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the cleaningcomposition.

In some embodiments, the granular absorbent material contains ceramicminerals. In some embodiments, the granular absorbent material containsperlite and/or vermiculite. In some embodiments, the granular absorbentmaterial has a surface area per mass ratio in the range of 100-10,000m²/g, 100-9,000 m²/g, 100-8,000 m²/g, 300-8,000 m²/g, 1,000-8,000 m²/g,2,000-8,000 m²/g, 3,000-8,000 m²/g, 4,000-8,000 m²/g, 5,000-8,000 m²/g,6,000-8,000 m²/g, 7,000-8,000 m²/g, 100-7,000 m²/g, 300-7,000 m²/g,1,000-7,000 m²/g, 2,000-7,000 m²/g, 3,000-7,000 m²/g, 4,000-7,000 m²/g,5,000-7,000 m²/g, 6,000-7,000 m²/g, 100-6,000 m²/g, 300-6,000 m²/g,1,000-6,000 m²/g, 2,000-6,000 m²/g, 3,000-6,000 m²/g, 4,000-6,000 m²/g,5,000-6,000 m²/g, 100-4,000 m²/g, 300-4,000 m²/g, 1,000-4,000 m²/g,2,000-4,000 m²/g, 3,000-4,000 m²/g, 100-3,000 m²/g, 300-3,000 m²/g,1,000-3,000 m²/g, 2,000-3,000 m²/g, 100-2,000 m²/g, 300-2,000 m²/g, or1,000-2,000 m²/g.

In some embodiments, the granular absorbent material has a surface areaper mass ratio up to 10,000 m²/g. In some embodiments, the granularabsorbent material has a surface area per mass ratio up to 9,000 m²/g.In some embodiments, the granular absorbent material has a surface areaper mass ratio up to 8,000 m²/g. In some embodiments, the granularabsorbent material has a surface area per mass ratio up to 7,000 m²/g.In some embodiments, the granular absorbent material has a surface areaper mass ratio up to 6,000 m²/g.

In some embodiments, the granular absorbent material has a surface areaper mass ratio of 100 m²/g or greater. In some embodiments, the granularabsorbent material has a surface area per mass ratio of 300 m²/g orgreater. In some embodiments, the granular absorbent material has asurface area per mass ratio of 1,000 m²/g or greater. In someembodiments, the granular absorbent material has a surface area per massratio of 2,000 m²/g or greater. In some embodiments, the granularabsorbent material has a surface area per mass ratio of 3,000 m²/g orgreater. In some embodiments, the granular absorbent material has asurface area per mass ratio of 4,000 m²/g or greater. In someembodiments, the granular absorbent material has a surface area per massratio of 5,000 m²/g or greater.

In some embodiments, the granular absorbent material has a surface areaper mass ratio in the range of 1000-6,000 m²/g.

In some embodiments, the granular absorbent material has a surface areaper volume ratio in the range of 100-5,000 m²/ml, 300-5,000 m²/ml,1,000-5,000 m²/ml, 2,000-5,000 m²/ml, 3,000-5,000 m²/ml, 4,000-5,000m²/ml, 100-4,000 m²/ml, 300-4,000 m²/ml, 1,000-4,000 m²/ml, 2,000-54,000m²/ml, 3,000-4,000 m²/ml, 100-3,000 m²/ml, 300-3,000 m²/ml, 1,000-3,000m²/ml, 2,000-3,000 m²/ml, 100-2,000 m²/ml, 300-2,000 m²/ml, or1,000-2,000 m²/ml.

In some embodiments, the granular absorbent material has a surface areaper volume ratio up to 5,000 m²/ml. In some embodiments, the granularabsorbent material has a surface area per volume ratio up to 4,000m²/ml. In some embodiments, the granular absorbent material has asurface area per volume ratio up to 3,000 m²/ml.

In some embodiments, the granular absorbent material has a surface areaper volume ratio of 100 m²/ml or greater. In some embodiments, thegranular absorbent material has a surface area per volume ratio of 300m²/ml or greater. In some embodiments, the granular absorbent materialhas a surface area per volume ratio of 1,000 m²/ml or greater. In someembodiments, the granular absorbent material has a surface area pervolume ratio of 2,000 m²/ml or greater. In some embodiments, thegranular absorbent material has a surface area per volume ratio in therange of 1000-3,000 m²/ml.

In some embodiments, the granular absorbent material constitutes 10-70%(w/w), 10-60% (w/w), 10-50% (w/w), 10-40% (w/w), 10-30% (w/w), 10-20%(w/w), 20-70% (w/w), 20-60% (w/w), 20-50% (w/w), 20-40% (w/w), 20-30%(w/w), 30-70% (w/w), 30-60% (w/w), 30-50% (w/w), 30-40% (w/w), 40-70%(w/w), 40-60% (w/w), 40-50% (w/w), 50-70% (w/w), 50-70% (w/w) or 60-70%(w/w) of the cleaning composition. In some embodiments, the granularabsorbent material constitutes 25-30% (w/w) of the final product. Insome embodiments, the granular absorbent material constitutes about 27%(w/w) of the cleaning composition.

In some embodiments, the cleaning composition further comprises asanitation agent absorbed in the coated granular absorbent material.Examples of the sanitation agent have been described above.

In some embodiments, the sanitation agent comprise an active substancedesigned to destroy, inhibit, reduce activity, inhibit grow or otherwiserender harmless harmful organisms or toxic chemicals. In someembodiments, the sanitation agent is a liquid phase agent. In someembodiment, the sanitation agent is a liquid phase biocide. In someembodiment, the sanitation agent is a liquid phase chemical thatinactivates toxic chemicals, such as chemo therapy drugs.

Examples of liquid phase biocide include, but are not limited to,chlorine bleach solutions, hydrogen peroxide solutions, peracetic acid,quaternary amine solutions, periodine, alcohol solutions, dimethylbenzyl ammonium chloride, dimethyl ethybenzyl ammonium chloride andmixtures thereof.

Examples of liquid phase chemicals that can be used to inactivate orremove toxic chemicals include, but are not limited to, anionicsurfactants such as soap, sulfonates and sulfates. In some embodiments,large quantities of water is used to dilute the toxic chemicals.

In some embodiments, the sanitation agent constitutes 0.1 to 10% (w/w),0.1 to 3% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 10% (w/w),0.3 to 3% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 3% (w/w) or 3 to10% (w/w) of the cleaning composition.

In some embodiments, the sanitation agent comprises dimethyl benzylammonium chloride or dimethyl ethybenzyl ammonium chloride. In someembodiments, the sanitation agent comprises a mixture of dimethyl benzylammonium chloride or dimethyl ethybenzyl ammonium chloride. In someembodiments, the sanitation agent is a 1:1 mixture of dimethyl benzylammonium chloride or dimethyl ethybenzyl ammonium chloride.

In some embodiments, the cleaning composition further comprises one ormore modifying agent. Examples of the sanitation agent have beendescribed above. In some embodiments, the modifying agent comprises athickening agent, a tackifier, a gum, an absorbent polymers orcombinations thereof. In some embodiments, the one or more modifyingagents comprise a carboxymethyl cellulose (CMC)-derived polymer and/or ahierarchically porous carbons (HPC)-derived polymer.

In some embodiments, the one or more modifying agents further compriseone or more additives selected from the group comprising denaturingagents, colorant agents, odor correctors, and/or pH regulators.

In some embodiments, the one or more modifying agents constitute 0.1 to5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5%(w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or2 to 5% (w/w) of the cleaning composition.

In some embodiments, the cleaning composition has a liquid loadingcapability in the range of 10-50% by volume, 15-45% by volume, 20-40% byvolume, 25-35% by volume, or 25-30% by volume. In other embodiments, thecleaning composition has a liquid loading capability of 100-400% by massaddition, 150-350% by mass addition, or 200-300% by mass addition. Insome embodiments, the cleaning composition of the present application iscapable of absorbing liquid at a liquid loading of 25-30% by volume or200-300% by mass addition.

Method of Use

Another aspect of the present application relates to a method of usingthe cleaning composition of the present application. The methodcomprises the steps of applying an effective amount of the cleaningcomposition of the present application to a surface in need of cleaning,and remove the cleaning composition after a period of time.

In some embodiments, the period of time is from 30 seconds to 30minutes. In some embodiments, the period of time is from 1 to 30minutes, from 1 to 20 minutes, from 1 to 10 minutes, from 2 to 30minutes, from 2 to 20 minutes, from 2 to 10 minutes, from 5 to 30minutes, from 5 to 20 minutes and from 5 to 10 minutes.

In some embodiments, the surface in need of cleaning comprises abiohazard spill. In some embodiments, the biohazard spill is vomit,urine, blood, feces, and/or a chemo therapy drug. In some embodiments,the surface in need of cleaning is a surface in a public area and needsto be treated to prevent or reduce cross contamination or infection. Asused herein, the term “public area” includes, but is not limited to,hospitals, doctors' offices, urgent care facilities, nursing homes,prisons and related correction facilities, schools, buses, aircraft,airports, bars, restaurants, hotels, amusement parks, any largegathering institution facilities, veterinary facilities and drugresearch and development facilities. In some embodiments, the publicarea is located in a hotel.

In some embodiments, the method further comprises the step of: washingthe treated surface with a liquid or wiping the surface with a wipingmaterial, such as paper tower or mops, after the removal of the cleaningcomposition.

Another aspect of the present application relates to a method ofdisinfecting an affected area to prevent or reduce the distribution ofpathogens such as viruses and bacteria. The method comprises the stepsof apply an effective amount of the cleaning composition of the presentapplication to the affected area and remove the cleaning compositionafter a period of time, wherein the cleaning composition contains agranular absorbent material coated with a static, surface bonded film ofbiocide selected from the group consisting of silanes, siloxanes,aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides,silver and salts of silver, copper and salts of copper. In someembodiments, the cleaning composition further comprises a sanitationagent selected from the group consisting of chlorine bleach solutions,hydrogen peroxide solutions, per acetic acid, quaternary amine solutionsand alcohol solutions. In some embodiments, the sanitation agent isadded to the cleaning composition immediately prior to the applicationto the affected area.

In some embodiments, the cleaning composition of the present applicationis a multi-phase product that can be used to kill microbes through anumber of different mechanisms. In one embodiment, the composition is adoped granular ceramic disinfectant which combines a surface area staticdisinfectant or biocide coating with a chemical phase primarydisinfectant or biocide absorbed in the ceramic particles. As usedherein, the term “disinfectant” describes the composition andformulations described herein for the elimination of pathogens fromsurfaces. As used herein, the term “disinfect” shall mean theelimination of many or all pathogens on a surface to which disinfectantis administered.

In some embodiments, the cleaning composition of the present applicationis a surface area solid phase disinfectant that combines with a superabsorbent polymer so that liquid loadings (e.g., 25-30% byvolume/200-300% by mass addition) of available liquid can be added so asto impart chemical disinfection, to impart deodorizing chemicals or toimpart a blanketing effect on the affected area so as to reduce thespread of microbe into the open air.

In some embodiments, the cleaning composition of the present applicationis a high surface area solid phase disinfectant with the addition oftackifiers, so that it lays on a bio hazard and forms a blanket whichgreatly reduces the release of airborne pathogens.

The following examples are offered by way of illustration of certainembodiments of aspects of the application herein. None of the examplesshould be considered limiting on the scope of the application.

Kits

Another aspect of the present application relates to a cleaning kit. Thekit can be used for cleaning up hazardous materials, such as vomit,urine, blood, feces, and/or a spill of chemo therapy drug, ordisinfecting a surface. In some embodiments, the kit contains thecleaning composition of the present application and instructions on howto use the cleaning composition.

In some embodiments, the kit further contains a copy of OSHA guidelines.In some embodiments, the kit further contains one or more of thefollowing: biohazard bags, gloves, twist tie, antimicrobial hand wipe,germicidal wipe, scoop/scraper.

The cleaning kit can be conveniently placed in locations within quickreach of all caregivers. For example; all patient and chemotherapyrooms, case & crash carts, emergency vehicles, cafeteria, environmentalservices closets, and within or near first aid kits, etc.

Example 1: Tests of the Virucidal Effect of the Cleaning Composition ofthe Present Application

Grow VR-728 Feline Calicivirus Strain F-9

Materials: CCL-94 cells, T-75 flask with CCL-94 cells, 70% confluent, 6well plates with CCL-94 cells, 70% confluent, EMEM, FBS, VR-728 Felinecalicivirus Strain F-9, 50 ml conical tube, Serological pipette,stripettes, 35° C. Incubator, CleanUp,

-   -   Methods    -   1. Viral stock=1:10 dilution, 1 ml virus+9 ml serum free EMEM    -   2. Remove medium from all flasks and plates    -   3. Add serum free media and virus to each flask and plat        -   a. Flask 1: 2 ml virus+8 ml media        -   b. Flask 2: 1.5 ml virus+8.5 ml media        -   c. Plate 1: virus+media in all 6 cells        -   d. Plate 2

13 mg clean up 7.5 mg Clean Up Virus  1 mL media   1 ml media MediaCells 13 mg clean up 7.5 mg Clean Up Virus  1 mL media   1 ml mediaMedia Cells

-   -   4. Incubate at 35° C. for 1½ hours    -   5. Prepare media: EMEM+2% FBS and filter    -   6. Add 15 ml media to each flask    -   7. Add 1 ml media to each well in each plate        Harvest VR-728 Feline Calicivirus Strain F-9    -   1. Combine media from Flask 1 and 2 and Plate 1    -   2. Cells were divided into 10, 15 ml conical tubes containing 10        ml virus each    -   3. Store at −80° C.

Materials: VR-728 Feline calicivirus Strain F-9, EMEM+2% FBS, CleanUp,6-well plates with CCL-94 Cells, 70% confluent, Beaker, 1.5 mlcentrifuge Tube, Centrifuge, 35° C. incubator, Cell Scraper, CellCounter

-   -   Methods    -   1. Virus diluted in EMEM+2% FBS at 1:50.    -   2. Measure 2 sets of 2 g, 3 g, 4 g, 5 g, 6 g of CleanUp and        place each in a separate beaker. one set for 5 minutes, and one        set for 10 minutes, autoclave.    -   3. Add 4 ml virus to 6 ml Cleaning Powder and allow it to sit        for 5 minutes.    -   4. Remove Clean Up from each beaker.    -   5. Add 3 ml media to each beaker.    -   6. Repeat steps 3-5 for 10 minutes.    -   7. Take 1 ml from each beaker and add to a 1.5 ml centrifuge        tube. Centrifuge at 2200RPM, 4° C., 4 minutes.    -   8. Remove media from plate containing CCL-94 cells.    -   9. Add 30 μl Clean Up and 3 ml media to each well    -   10. Incubate for one hour.    -   11. Scrape Cells and place media into 15 ml tubes.    -   12. Determine cell death    -   Plate Set-Up

Cells + 1 g Clean Up Cells + 1 g Clean Up Cells Cells + Virus Cells +Virus Cells

-   -   Results    -   Compared to untreated virus samples, virus samples treated with        CleanUp showed significantly reduced cytotoxicity, indicating        activation of the virus by CleanUp.

Example 2: Tests of the Cleaning Composition of the Present Applicationwith the Initial Virucidal Effectiveness Test

The virucidal effect of the cleaning composition of the presentapplication is further tested using the Initial Virucidal EffectivenessTest protocol provided by the Antimicrobials Division of the UnitedStates Environmental Protection Agency (USEPA).

Briefly, this test is designed to validate virucidal effectivenessclaims for a product to be registered as a virucide. It determines thepotential of the test agent to disinfect hard, non-porous surfacescontaminated with NOROVIRUS. This test is designed to simulate consumeruse, conforms to EPA Guidelines DIS/TSS-7, November 1981, and followsthe general procedure outlined in the FR notice for another surrogatevirus available online1 and Virucidal Testing Format and StatisticsPrimer issued by EPA (March 2000).

-   -   TESTING CONDITIONS: Two lots of the test agents will be used to        inactivate the challenge virus that has been dried on a sterile        glass surface (two replicates for each batch/lot of the test        agents). The test agent will be tested in a manner consistent        with the label directions for use of the test agent or as        specified by the Sponsor.    -   MATERIALS:    -   A. Test control and reference substances: supplied by the        Sponsor (see last page)_The test agent will be tested as        supplied by the Sponsor unless directed otherwise. The Sponsor,        before the initiation of testing, must specify all operations        performed on the test agent such as dilutions of the test agent,        the diluent for the test agent, or specialized storage        conditions.

The test agent must be tested for identity, strength, purity, stabilityand uniformity as applicable. All unused test agent will be retained fora period after completion of the test, then discarded in a manner thatmeets the approval of the safety officer.

-   -   B. Materials can include, but are not limited to:    -   1. Challenge virus as requested by the sponsor of the study:        Feline calicivirus (American Type Culture Collection, Manassas,        Va.; ATCC VR-782).    -   2. Host cell line: Crandel Reese Feline Kidney (CRFK) cell        (American Type Culture Collection, Manassas, Va.; ATCC CCL-94).        CRFK cells will be grown in Cell Culture Media (Eagle's Minimum        Essential Media containing $5% Fetal Bovine Serum) containing        Fetal Bovine Serum (FBS). The FCV will be grown by inoculating        confluent cell monolayers, no more than 24-48 hours in age,        using low multiplicity of infection (MOI). Briefly, a flask of        host cells grown in cell culture media containing 10% fetal        bovine serum (FBS) will be used. The percent FBS contained in        the stock virus aliquot will be adjusted to yield a minimum of a        5% organic soil load. Cells will be washed three times with        phosphate buffered saline (PBS) and inoculated with virus.        Post-virus adsorption, the cell monolayer will be washed once in        Earle's balanced salt solution (EBSS), re-fed with cell culture        media and incubated. The cytopathic effects (CPE) will be        described as small, rounding of the cells, with a slight        granular look. The CPE will start to develop in 1-2 days        following inoculation, and will be harvested when more than 90%        cytopathic effects (CPE) are observed. Post-incubation, the        cells will be disrupted, with cell debris removed by        centrifugation. Stock virus will be prepared by collecting the        supernatant culture fluid from 75-100% infected culture cells.        The supernatant will be removed, aliquoted, and stored in an        ultra-low temperature freezer until the day of use. On the day        of use an aliquot will be removed, thawed and refrigerated until        use in the assay.    -   3. Laboratory equipment and supplies, and    -   4. Media and reagent:    -   a. Cell Culture Media (Eagle's Minimum Essential Media        containing $5% Fetal Bovine Serum)    -   b. Earle's Balanced Salt Solution (EBSS)    -   c. Fetal Bovine Serum (FBS)    -   d. Phosphate Buffered Saline (PBS)    -   e. Sephadex™/Sephacryl™ columns (if necessary)    -   f. Neutralizer

TEST SYSTEM IDENTIFICATION: All Petri dishes, dilution tube racks, andhost-containing apparatus will be labeled with the followinginformation: virus, host, test agent, and project number.

EXPERIMENTAL DESIGN

A. Inoculum preparation: The F-9 strain of Feline calicivirus (FCV) willbe obtained from the American Type Culture Collection, Manassas, Va.,(ATCC VR-782). The FCV will be grown by inoculating confluent cellmonolayers, no more than 24-48 hours in age, using low multiplicity ofinfection (MOI). Briefly, a flask of host cells grown in cell culturemedia containing 10% fetal bovine serum (FBS) will be used. Cells willbe washed three times with phosphate buffered saline (PBS) andinoculated with virus. Post-virus adsorption, the cell monolayer will bewashed once in Earle's balanced salt solution (EBSS), re-fed with cellculture media and incubated. The cytopathic effects (CPE) are describedas small, rounding of the cells, with a slight granular look. The CPEstarts to develop in 1-2 days following inoculation, and will beharvested when more than ninety percent cytopathic effects (CPE) areobserved. Post-incubation, the cells will be disrupted, with cell debrisremoved by centrifugation.

Stock virus will be prepared by collecting the supernatant culture fluidfrom 75-100% infected culture cells. The supernatant will be removed,aliquoted, and stored in an ultra-low temperature freezer until the dayof use. On the day of use an aliquot is removed, thawed and refrigerateduntil use in the assay. The percent FBS contained in the stock virusaliquot is adjusted to yield a minimum of a 5% organic soil load. If theSponsor chooses a soil load greater than 5%, the percent FBS containedin the stock virus aliquot will be adjusted to yield the percent soilload requested.

B. Carrier Preparation: An aliquot of 0.2 ml stock virus will be spreaduniformly over the bottoms of 100×15 mm sterile glass Petri dishes witha cell scraper. The virus will be air-dried at room temperature for30-60 minutes (until visibly dry). The drying conditions (temperatureand humidity) will be appropriate for the test virus to obtain maximumsurvival following drying. The actual drying time and temperature willbe recorded. Two carriers will be prepared for each lot of test agentand plate recovery control. Additionally, one carrier per test agent lotwill be prepared for the neutralizer effectiveness control using cellculture media in place of stock virus.

C. Test agent preparation: The test agent will be prepared and usedaccording to the Sponsor's directions or proposed label claims.

D. Test: For each of two batches of test substance, two dried virusfilms will be exposed to 2.0 ml of the use dilution of the testsubstance, or to the amount of spray released under use conditions(spray products) for a specified exposure time and temperature. Postcontact time, the test agent will be neutralized and the mixture will bescraped from the surface of the dish. This will be consideredapproximately one log₁₀ dilution.

1. Sephadex™/Sephacryl™ Filtration. If columns are utilized, each samplewill be loaded into individual pre-spun Sephadex™/Sephacryl™ columns.Virus-test substance mixture will be passed through individual columnsutilizing the syringe plunger or centrifugation in order to detoxify themixture. The aseptically collected samples will be diluted asappropriate.

2. If columns are not used, serial tenfold dilutions of neutralizedvirus will be prepared in cell culture media. For spray-type agents, theagent will be used as per Sponsor's instructions, the volume produced bythe spray product during the spraying application specified by thesponsor will be measured prior to testing and an equivalent quantity ofthe neutralizer will be applied post contact time. Following applicationof the test agent, contact time, and neutralization, the procedure forprocessing the samples will the same as described earlier (see above).

E. Infection, cell maintenance and infectivity assays: Selecteddilutions of the neutralized inoculum/test agent mixture will be addedto cultured cell monolayers. Four wells per dilution will be added tothe host cell monolayers and incubated at 37±2° C. in 5±1% CO₂ for 5-7days. Post incubation the infectious FCV will be scored microscopicallyby observing virus-specific cytopathic effects (CPE) produced byreplicating infectious virus. The CPE associated with FCV is visuallyevidenced under the microscope by the presence of small, shrinking cellsthat have detached from the monolayer. These changes will be scored incomparison with the negative control (cell viability control).

F. Controls: All controls will be performed at the same time as thetest, incubated under the same conditions and assayed in the same manneras the test (see above). Neutralizer effectiveness control, Cytotoxicitycontrol and Cytotoxicity-related viral interference control will beperformed for test agent(s).

1. Cell viability. control This control will demonstrate that cellsremain viable throughout the course of the assay period. In addition, itwill confirm sterility of the cell culture employed throughout the assayperiod. Four wells will receive cell culture media only.

2. Virus stock titer. The challenge virus will be titered at the time ofthe test to determine the relative infectivity of the virus and todemonstrate the susceptibility of the host cells to support infection ofFCV. The virus inoculum will be serial diluted tenfold in cell culturemedia. Selected dilutions will be inoculated into four wells perdilution and incubated under the same conditions as the test.

3. Plate recovery control (PRC). Two ml of cell culture media will beadded to the dried virus. Post-contact time, the virus/cell culturemixture will be subjected to the identical neutralization procedure asthe test agent. If columns are used, a portion of the virus/cell culturemedia/neutralizer mixture will be used for the column titer control (seebelow). This control will determine the relative loss in virusinfectivity resulting from drying and neutralization alone. The resultsfrom the PRC will be compared with the test results to confirm recoveryof at least four log₁₀ of infectious virus following drying andneutralization. Its titer will be used to compare with the titers of thetest results to reach the acceptable test criteria (see below).

4. Neutralizer effectiveness control (NEC). The neutralization procedurewill be dependent upon the active ingredient present in the test agentand in the internal control test agent. For this control, each lot ofthe test agent will be processed exactly as the test procedure, butinstead of the viral inoculum, cell culture media will be added. Postneutralization, the sample will be divided into three portions [two forcytotoxicity related controls (see below) and one for neutralizereffectiveness].

If columns are used, each sample will be passed through individualcolumns and the eluate will be serial diluted as appropriate in cellculture media. If columns are not used, the neutralizer effectivenesssamples will be serial diluted tenfold in cell culture media. Thediluted samples will be mixed with low titer virus, held for a periodequivalent to contact time and assayed for viral infectivity and/orcytotoxicity (see below), in order to determine the dilution of testagent at which virucidal activity, if any, is retained. Then theselected dilutions will be used to inoculate host cells as described forthe test procedure. Dilutions that show virucidal activity will not beconsidered in determining reduction of viral infectivity by the testagent.

5. Cytotoxicity control (CT). A CT control will be run to determine ifthe product is toxic to the cells. Each lot of the neutralized testagent will be run to determine cytotoxicity. The CT sample, acquiredfrom the NEC, will be serial diluted tenfold in cell culture media,having no virus added. Selected dilutions will be inoculated andincubated in the same manner as the test and control samples.

G. Calculations. Viral and cytotoxicity titers will be expressed as−log₁₀ of the 50 percent titration endpoint infectivity (TCID₅₀),respectively, as calculated by the method of Spearman Karber.

−Log of 1^(st) dilution inoculated−[(Sum of % mortality at eachdilution/100)−0.5)×(logarithm of dilution)]

The log₁₀ reduction in infectivity will be calculated using the revisedEPA approved method for calculating the Most Probable Number (MPN) asobtained from the EPA on Jan. 4, 2001.

Example 3: Testing of Efficacy in Different Environments and AgainstMultiple Pathogens

The cleaning composition of the present application is tested foreffectiveness according to EPA standard operating procedures to measurethe effectiveness of hard surface disinfectants against Staphylococcusaureus, Pseudomonas aeruginosa, Salmonella choleraesuis, Mycobacteriumbovis, Clostridium difficile, and viruses. The standard operatingprocedures are based on strict interpretations of AOAC International andASTM International standard methods.

In an exemplary test, the cleaning composition of the presentapplication is tested as a germicidal spray product with testing foreffectiveness against Staphylococcus aureus, Pseudomonas aeruginosa andSalmonella enterica (EPA Method ID: MB-06-08 dated Sep. 22, 2014).

Test cultures of the bacterium are prepared as follows: Defrost a singlecryovial at room temperature and briefly vortex to mix. Add 10 μL of thethawed frozen stock (single use) to a tube containing 10 mL of culturemedium (Synthetic broth is used for S. aureus, P. aeruginosa and S.enterica. Nutrient broth may be used for P. aeruginosa.). Vortex, andincubate at 36±1° C. for 24±2 h. One daily transfer is required prior tothe inoculation of a final test culture. Daily cultures may besubcultured for up to 5 days; each daily culture may be used to generatea test culture. For S. aureus and S. enterica only, briefly vortex the24 h cultures prior to transfer. For the final subculture transfer,inoculate a sufficient number of 20×150 mm tubes containing 10 mL growthmedium (e.g., synthetic broth or nutrient broth) with 10 μL per tube ofthe 24 h culture then vortex to mix. Incubate 48-54 h at 36±1° C.without shaking.

Carrier inoculation is carried out as follows: Inoculate approximately80 carriers; 60 carriers are required for testing, 6 for control carriercounts, and 1 for the viability control. For P. aeruginosa, remove thepellicle from the broth either by decanting the liquid aseptically intoa sterile tube, by gently aspirating the broth away from the pellicleusing a pipette, or by vacuum removal. Avoid harvesting pellicle fromthe bottom of the tube. Transfer test culture after pellicle removalinto sterile 25×150 mm test tubes (up to approximately 20 mL per tube)and visually inspect for pellicle fragments. Presence of pellicle in thefinal culture makes it unusable for testing.

For S. aureus and S. enterica, using a vortex-style mixer, mix 48-54 htest cultures 3-4 s and let stand 10 min at room temperature beforecontinuing. Remove the upper portion of each culture (e.g., upper 3/4 orapproximately 7.5 mL), leaving behind any debris or clumps, and transferto a sterile flask; pool cultures in the flask and swirl to mix.

For S. aureus, P. aeruginosa and S. enterica, using a vortex-stylemixer, mix 48-54 h test cultures 3-4 s and let stand 10 min at roomtemperature before continuing. Remove the upper portion of each culture(e.g., upper ¾ or approximately 7.5 mL), leaving behind any debris orclumps, and pool culture into a sterile flask; swirl to mix. Measure andrecord the OD at 650 nm. Use sterile broth medium to calibrate thespectrophotometer. Note: To achieve mean carrier counts within theappropriate range (see section 8), the final test culture may be diluted(e.g., one part culture plus one part sterile broth) prior to theaddition of the OSL to the inoculum using the sterile culture mediumused to generate the final test culture (e.g., synthetic broth). Use thediluted test culture for carrier inoculation within 30 min. Addappropriate amount of organic burden if required. Swirl to mix.

Vortex-mix the inoculum periodically during the inoculation of carriers.Use a calibrated positive displacement pipette to transfer 0.01 mL ofthe culture to the sterile test carrier in the Petri dish. Immediatelyspread the inoculum uniformly using a sterile loop. Do not allow theinoculum to contact the edge of the glass slide carriers. Cover dishimmediately. Dry carriers in incubator at 36±1° C. for 30-40 min.Perform efficacy testing within two hours of drying.

Enumeration of viable bacteria from carriers (control carrier counts) isconducted as follows: Assay dried carriers in 2 sets of three carriers,one set immediately prior to conducting the efficacy test and one setimmediately following the test. Randomly select 6 inoculated carriersfor carrier count analysis prior to efficacy testing. Place each of theinoculated, dried carriers in a 38×100 mm culture tube or sterile 50 mLpolypropylene conical tube containing 20 mL of letheen broth. Vorteximmediately −60±5 seconds for P. aeruginosa or 120±5 seconds for S.aureus and S. enterica. After vortexing, briefly mix and make serialten-fold dilutions in 9 mL dilution blanks of PBDW. Briefly vortex andplate 0.1 mL aliquots of appropriate dilutions in duplicate on TSA orBAP using spread plating. Plate appropriate dilutions to achieve colonycounts in the range of 30-300 colony forming units (CFU) per plate.Spread inoculum evenly over the surface of the agar. Plates must be dryprior to incubation. If the serial dilutions are not made and platedimmediately, keep the tubes at 2-5° C. until this step can be done.Complete the dilutions and plating within 2 h after vortexing.Alternatively, pool the letheen broth from the tubes with the carriersand briefly vortex. Serially dilute and plate 0.1 mL aliquots of thepooled media (60 mL). The average carrier count per set will becalculated. Incubate plates (inverted) at 36±1° C. for up to 48±2 h.Count colonies.

Disinfectant sample preparation is conducted as follows: For aerosolcans and trigger or pump sprayers, shake the can 25 times prior to use,unless otherwise specified by the manufacturer. Spray the test substancefor 10-15 seconds prior to testing to ensure sprayer is operatingcorrectly and test substance is dispensed properly. For concentratedtest substances, aseptically prepare the test substance use-dilutionrequired for the test using appropriate sterile glassware or pipettes.For concentrated test substances, use ≥1.0 mL or 1.0 g of the testsubstance sample to prepare the final solution to be tested. Use v/vdilutions for liquid test substances and w/v dilutions for solids. Priorto testing, wipe the spray nozzle using 70% ethanol and sterile gauzeand allow to dry.

The test procedure is conducted as follows: After the required carrierdrying time, spray the slides sequentially for a specified time,distance, and number of pumps at timed intervals (typically 30 seconds)with the carriers in a horizontal position. Use a certified timer totime the spray interval. Spray the slide within ±5 seconds of thespecified time for a contact time of 1-10 minutes or within ±3 secondsfor contact times <1 minute. After spraying, maintain the carriers in ahorizontal position. Treated carriers must be kept undisturbed duringthe contact time. After the last slide of a set (typically 20 slides)has been sprayed with the disinfectant, and the exposure time iscomplete, sequentially transfer each slide into the primary subculturetube containing the appropriate neutralizer within the ±5 second timelimit. Drain the excess disinfectant from each slide prior to transferinto the neutralizer tube. Drain carriers without touching the Petridish or filter paper. Perform transfers with flame sterilized orautoclaved forceps. The slide can touch both the interior sides of thePetri dish and the subculture tube during the transfer, but avoid thiscontact as much as possible. After the slide is deposited, recap thesubculture tube and shake culture thoroughly. Incubate at 36±1° C. for48±2 h.

Results are recorded as follows: Gently shake each tube prior torecording results. Record results as +(growth) or 0 (no growth) asdetermined by presence or absence of turbidity. Confirm a minimum ofthree positive carrier sets per test. If there are less than threepositive carriers, then confirm each carrier.

The cleaning composition of the present application is tested againstthe parameters set by the EPA in the Series 810—Product Performance TestGuidelines, specifically public health uses of disinfectants (OCSPP810.2200 (EPA-HQ-OPPT-2009-0150-0029)). To demonstrate efficacy, testingis conducted against Salmonella enterica (S. enterica), formerlydesignated as Salmonella choleraesuis, American Type Culture Collection(ATCC) 10708 for effectiveness against Gram-negative bacteria, orStaphylococcus aureus (S. aureus) (ATCC 6538) for effectiveness againstGram-positive bacteria. Three batches of the product are tested at thelower certified limit (LCL). For each batch, sixty carriers are used inthe test. Three independent tests (i.e., three batches tested once onthree different test days) are conducted against the test microbe at theLCL. The performance standard for S. aureus is 0-3 positive carriers outof sixty. The performance standard for S. enterica is 0-1 positivecarriers out of sixty. Contamination of one carrier (culture tube) isallowed per 60-carrier set; occurrence of more than one contaminatedcarrier invalidates the test results. For germicidal spray products, theproduct should kill the test microorganisms on 59 out of each set of 60carriers/slides. Contamination of only one carrier (culture tube) isallowed per 60-carrier set; occurrence of more than one contaminatedcarrier invalidates the test results.

For use as a hospital or healthcare disinfectant, to demonstrateefficacy, testing is conducted against S. aureus (ATCC 6538) andPseudomonas aeruginosa (ATCC 15442). For use against fungus, todemonstrate efficacy, testing is conducted against Trichophytonmentagrophytes (ATCC 9533). For use against viruses, testing isconducted against Hepatitis B virus, Hepatitis C virus, and Norovirus,the Duck Hepatitis B virus, Bovine Viral Diarrhea virus, and FelineCalicivirus, respectively, which are considered acceptable surrogatesfor testing.

While various embodiments have been described above, it should beunderstood that such disclosures have been presented by way of exampleonly and are not limiting. Thus, the breadth and scope of the subjectcompositions and methods should not be limited by any of theabove-described exemplary embodiments, but should be defined only inaccordance with the following claims and their equivalents.

The above description is for the purpose of teaching the person ofordinary skill in the art how to practice the object of the presentapplication, and it is not intended to detail all those obviousmodifications and variations of it which will become apparent to theskilled worker upon reading the description. It is intended, however,that all such obvious modifications and variations be included withinthe scope of the present application, which is defined by the followingclaims. The aspects and embodiments are intended to cover the componentsand steps in any sequence, which is effective to meet the objectivesthere intended, unless the context specifically indicates the contrary.

What is claimed is:
 1. A method of formulating a cleaning composition,comprising the steps of: (a) grinding an absorbent material to produce agranular absorbent material, wherein the granular absorbent materialconstitutes 10-50% (w/w) of the cleaning composition or wherein thegranular absorbent material does not comprise perlite; (b) coating thegranular absorbent material with a biocide to produce a coated absorbentmaterial, wherein the coating agent forms a surface bonded film on thegranular absorbent material; and (c) mixing the coated absorbentmaterial with a sanitation agent so that the coated absorbent materialabsorbs the sanitation agent to form the cleaning composition.
 2. Themethod of claim 1, wherein the biocide is selected from the groupconsisting of silanes, siloxanes, aminopropyltrimethoxysilane,quaternary amines, fumed metal hydroxides, solutions of silver,solutions of copper and combinations thereof.
 3. The method of claim 1,wherein the biocide is a liquid phase biocide.
 4. The method of claim 3,wherein the liquid phase biocide comprises one or more members selectedfrom the group consisting of chlorine bleach solutions, hydrogenperoxide solutions, peracetic acid, quaternary amine solutions, alcoholsolutions, periodine solutions, dimethyl benzyl ammonium chloride,dimethyl ethybenzyl ammonium chloride and mixtures thereof.
 5. Themethod of claim 1, wherein the biocide is applied to granular absorbentmaterial by vapor deposition, by a pressure micro droplet spray, or by afuming or fogging nozzle.
 6. The method of claim 1, wherein the granularabsorbent material has a surface area per mass ratio of 1,000 m²/g orgreater.
 7. The method of claim 1, wherein the granular absorbentmaterial has a surface area per volume ratio of 1,000 m²/ml or greater.8. The method of claim 1, wherein the sanitation agent is selected fromthe group consisting of chlorine bleach solutions, hydrogen peroxidesolution, peracetic acid, quaternary amine solutions, alcohol solutionsand combinations thereof.
 9. The method of claim 1, wherein thesanitation agent constitutes 0.1 to 10% (w/w) of the cleaningcomposition.
 10. The method of claim 1, wherein the biocide forms asurface bonded film on the granular absorbent material.
 11. The methodof claim 1, wherein the biocide constitutes 0.5 to 3.5% (w/w) of thecleaning composition.
 12. A method of using a cleaning composition,comprising: applying an effective amount of the cleaning composition ofclaim 1 to a surface in need of cleaning so as to form a treatedsurface; and removing the cleaning composition.
 13. The method of claim12, further comprising the step of washing the treated surface with aliquid or wiping the surface with a wiping material after the removal ofthe cleaning composition.
 14. The method of claim 12, wherein thecleaning composition is removed after treating the surface for a periodof time between 30 seconds to 30 minutes.
 15. The method of claim 12,wherein the surface in need of cleaning is in a public area.
 16. Themethod of claim 12, the surface in need of cleaning comprises abiohazard spill.
 17. The method of claim 1, wherein the granularabsorbent material constitutes 10-50% (w/w) of the cleaning composition.18. The method of claim 1, wherein the granular absorbent material doesnot comprise perlite.
 19. The method of claim 1, wherein the granularabsorbent material comprises vermiculite.